Engleman honored with 2026 AABB Landsteiner-Alter Award
The Association for the Advancement of Blood & Biotherapies (AABB) has selected Edgar Engleman, M.D., as the recipient of the prestigious 2026 Landsteiner-Alter Award, the organization’s highest scientific honor. This annual recognition celebrates individuals whose original research has profoundly influenced the fields of transfusion medicine or biotherapies on an international scale.
Dr. Engleman’s distinguished career encompasses pioneering contributions to both blood safety and cellular immunotherapy – advances that have reshaped modern medical practice and improved outcomes for patients worldwide. He used his monoclonal antibody to CD4 to develop the first test to identify asymptomatic AIDS carriers, and SBC successfully screened blood donors with this test to prevent the transmission of AIDS via transfusion – years before HIV was discovered. READ MORE
